DK3041475T3 - Pyrazol[1,5-A]pyrimidin-baserede forbindelser, sammensætninger omfattende disse, og fremgangsmåder til anvendelse deraf - Google Patents

Pyrazol[1,5-A]pyrimidin-baserede forbindelser, sammensætninger omfattende disse, og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK3041475T3
DK3041475T3 DK14766634.1T DK14766634T DK3041475T3 DK 3041475 T3 DK3041475 T3 DK 3041475T3 DK 14766634 T DK14766634 T DK 14766634T DK 3041475 T3 DK3041475 T3 DK 3041475T3
Authority
DK
Denmark
Prior art keywords
pyrazole
pyrimidine
compositions
methods
same
Prior art date
Application number
DK14766634.1T
Other languages
Danish (da)
English (en)
Inventor
Yingzhi Bi
Michael Walter Gardyan
Godwin Kumi
Yulian Zhang
Michael Alan Green
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3041475T3 publication Critical patent/DK3041475T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK14766634.1T 2013-09-06 2014-09-05 Pyrazol[1,5-A]pyrimidin-baserede forbindelser, sammensætninger omfattende disse, og fremgangsmåder til anvendelse deraf DK3041475T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361874395P 2013-09-06 2013-09-06
PCT/US2014/054209 WO2015035117A1 (en) 2013-09-06 2014-09-05 PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE

Publications (1)

Publication Number Publication Date
DK3041475T3 true DK3041475T3 (da) 2024-12-02

Family

ID=51542502

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14766634.1T DK3041475T3 (da) 2013-09-06 2014-09-05 Pyrazol[1,5-A]pyrimidin-baserede forbindelser, sammensætninger omfattende disse, og fremgangsmåder til anvendelse deraf

Country Status (12)

Country Link
US (2) US20150175610A1 (https=)
EP (1) EP3041475B1 (https=)
JP (1) JP6472450B2 (https=)
CN (1) CN105517553B (https=)
AR (1) AR097545A1 (https=)
AU (1) AU2014315113B2 (https=)
CA (1) CA2923317C (https=)
DK (1) DK3041475T3 (https=)
ES (1) ES3009382T3 (https=)
PT (1) PT3041475T (https=)
TW (1) TW201542550A (https=)
WO (1) WO2015035117A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3054955B1 (en) 2013-10-11 2018-05-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20180185368A1 (en) 2014-11-06 2018-07-05 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
EP4406616A3 (en) 2014-11-06 2024-11-06 Bial-R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
AU2017246455B2 (en) 2016-04-06 2021-09-30 Bial - R&D Investments, S.A. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
KR102530515B1 (ko) 2016-05-05 2023-05-09 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 이미다조[1,2-b]피리다진, 치환된 이미다조[1,5-b]피리다진, 관련 화합물, 및 의학적 장애의 치료에서의 그의 용도
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
CN113271940A (zh) * 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US7662826B2 (en) * 2002-04-23 2010-02-16 Shionogi & Co., Ltd. Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
WO2006099972A1 (en) 2005-03-23 2006-09-28 F. Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists
JP5048675B2 (ja) 2005-09-27 2012-10-17 エフ.ホフマン−ラ ロシュ アーゲー mGluR2アンタゴニストとしてのオキサジアゾリルピラゾロ−ピリミジン類
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ[1,5−a]ピリミジン化合物
WO2008045664A2 (en) * 2006-10-06 2008-04-17 Kalypsys, Inc. Heterocyclic pde4 inhibitors as antiinflammatory agents
JP2010508315A (ja) * 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
AR067326A1 (es) * 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
KR101324804B1 (ko) * 2008-05-13 2013-11-01 아이알엠 엘엘씨 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
MY169791A (en) * 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
WO2010135581A1 (en) 2009-05-20 2010-11-25 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as kinase inhibitors
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011073316A1 (en) * 2009-12-18 2011-06-23 Novartis Ag 4-aryl-butane-1,3-diamides
WO2011087999A1 (en) * 2010-01-14 2011-07-21 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidines as mark inhibitors
PL2710018T3 (pl) * 2011-05-19 2022-04-04 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Związki makrocykliczne jako inhibitory kinaz białkowych
CN104302649B (zh) * 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
DK2822555T3 (en) 2012-03-09 2018-02-05 Lexicon Pharmaceuticals Inc Inhibition of adapter-associated kinase 1 for the treatment of pain
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof

Also Published As

Publication number Publication date
PT3041475T (pt) 2025-01-07
CN105517553B (zh) 2020-03-27
US20150175610A1 (en) 2015-06-25
TW201542550A (zh) 2015-11-16
US20170081330A1 (en) 2017-03-23
AU2014315113A1 (en) 2016-03-10
AR097545A1 (es) 2016-03-23
EP3041475B1 (en) 2024-10-09
CN105517553A (zh) 2016-04-20
HK1217658A1 (zh) 2017-01-20
ES3009382T3 (en) 2025-03-26
JP2016529315A (ja) 2016-09-23
CA2923317A1 (en) 2015-03-12
AU2014315113B2 (en) 2018-10-04
CA2923317C (en) 2023-04-04
JP6472450B2 (ja) 2019-02-20
EP3041475A1 (en) 2016-07-13
US9862724B2 (en) 2018-01-09
WO2015035117A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
DK3041475T3 (da) Pyrazol[1,5-A]pyrimidin-baserede forbindelser, sammensætninger omfattende disse, og fremgangsmåder til anvendelse deraf
DK3359541T3 (da) N-sulfonylerede pyrazol[3,4-b]pyridin-6-carboxamider og fremgangsmåde til anvendelse
EP3055310A4 (en) Deubiquitinase inhibitors and methods for use of the same
DK3286181T3 (da) Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne
DK3628161T3 (da) Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
EP2948512A4 (en) HEATABLE THERMOFUSIBLE ADHESIVE COMPOSITIONS AND USE THEREOF
CA3284288A1 (en) Topical compositions and methods of using the same
DK4082530T5 (da) Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme
DK2816898T3 (da) Topiske sammensætninger omfattende fipronil og permethrin og fremgangsmåder til anvendelse
EP3054973A4 (en) Tm4sf1 binding proteins and methods of using same
EP3299366A4 (en) Substituted pyrazole compounds containing pyrimidine and preparation method and use thereof
DK2947084T3 (da) Fem- og seks-ledet heterocyklisk forbindelse og forberedelsesmetode, farmaceutisk sammensætning og anvendelse deraf
FR3003568B1 (fr) Composition comprenant hf et 3,3,3-trifluoro-2-chloropropene
EP3075727A4 (en) Pyrazole amide compound and use thereof
DK3089707T3 (da) Vævtransplantater og fremgangsmåder til fremstilling og brug af samme
ZA201605125B (en) Compositions comprising 15-hepe and methods of using the same
EP3013364A4 (en) Tuberculosis compositions and methods of using the same
EP3038622A4 (en) Heterocyclic compounds and methods of use
ZA201600238B (en) Stable liquid formulation of amg 416 (velcalcetide)
DK3022361T4 (da) Rambuk og fremgangsmåde til anvendelse deraf
WO2014130741A3 (en) Nme inhibitors and methods of using nme inhibitors
IL243613B (en) Consequences of mutated pyrazolylpyrazole and its use as a herbicide
IL243614A0 (en) Consequences of mutated pyrazolylpyrazole and its use as a herbicide
IL243615A0 (en) Consequences of mutated pyrazolylpyrazole and its use as a herbicide
IL258870A (en) Substituted indazole compounds as rorgammat inhibitors and uses thereof